메뉴 건너뛰기




Volumn 7, Issue 1, 2004, Pages 58-63

Canertinib Pfizer

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PD 0183805; PD 169414; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MORPHOLINE DERIVATIVE;

EID: 2142661651     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (6)

References (59)
  • 1
    • 33748184511 scopus 로고    scopus 로고
    • American Chemical Society 215th National Meeting (Part VI). ATP site-directed kinase inhibitors, Dallas, TX, USA
    • March 29-April 02
    • American Chemical Society 215th National Meeting (Part VI). ATP site-directed kinase inhibitors, Dallas, TX, USA. Denny WA IDDB MEETING REPORT 1998 March 29-April 02
    • (1998) IDDB Meeting Report
    • Denny, W.A.1
  • 2
    • 13144266690 scopus 로고    scopus 로고
    • Specific, irreversible inactivation of the epidermal growth factor receptor and ErbB2, by a new class of tyrosine kinase inhibitor
    • Specific, irreversible inactivation of the epidermal growth factor receptor and ErbB2, by a new class of tyrosine kinase inhibitor. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ et al PROC NATL ACAD SCI USA 1998 95 20 12022-12027 This study demonstrated the mechanism of action of irreversible inhibitors of ErbB-1 and ErbB-2 receptors at the ATP binding site.
    • (1998) Proc Natl Acad Sci USA , vol.95 , Issue.20 , pp. 12022-12027
    • Fry, D.W.1    Bridges, A.J.2    Denny, W.A.3    Doherty, A.4    Greis, K.D.5    Hicks, J.L.6    Hook, K.E.7    Keller, P.R.8    Leopold, W.R.9    Loo, J.A.10    McNamara, D.J.11
  • 3
    • 0031731295 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitors in cancer treatment (Part II)
    • Tyrosine kinase inhibitors in cancer treatment (Part II). Traxler P EXP OPIN THER PAT 1998 8 12 1599-1625
    • (1998) Exp Opin Ther Pat , vol.8-12 , pp. 1599-1625
    • Traxler, P.1
  • 4
    • 0033987746 scopus 로고    scopus 로고
    • Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
    • Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. Druker BJ, Lydon NB J CLIN INVEST 2000 105 1 3-7
    • (2000) J Clin Invest , vol.105 , Issue.1 , pp. 3-7
    • Druker, B.J.1    Lydon, N.B.2
  • 5
    • 33748127293 scopus 로고    scopus 로고
    • Drug development pipeline: PD-0183805
    • Warner Lambert Co January 24
    • Drug development pipeline: PD-0183805. Warner Lambert Co COMPANY COMMUNICATION 2000 January 24
    • (2000) Company Communication
  • 7
    • 0000742694 scopus 로고    scopus 로고
    • Investigation of the effects of the tyrosine kinase (TK) inhibitor Cl-1033 (PD0183805) against human tumor specimens taken directly from patients
    • Abs 3078
    • Investigation of the effects of the tyrosine kinase (TK) inhibitor Cl-1033 (PD0183805) against human tumor specimens taken directly from patients. Medina L, Gomez L, Cema C, Kraker A, Yochomowitz M, Weitman S PROC ANNU MEET AM ASSOC CANCER RES 2000 41 Abs 3078
    • (2000) Proc Annu Meet Am Assoc Cancer Res , vol.41
    • Medina, L.1    Gomez, L.2    Cema, C.3    Kraker, A.4    Yochomowitz, M.5    Weitman, S.6
  • 8
    • 0011873428 scopus 로고    scopus 로고
    • Irreversible inhibition of ErbB receptor family in rats results in epithelial atrophy and ulcerative dermatitis
    • Abs 3142
    • Irreversible inhibition of ErbB receptor family in rats results in epithelial atrophy and ulcerative dermatitis. Breider MA PROC ANNU MEET AM ASSOC CANCER RES 2000 41 Abs 3142
    • (2000) Proc Annu Meet Am Assoc Cancer Res , vol.41
    • Breider, M.A.1
  • 9
    • 33748210507 scopus 로고    scopus 로고
    • Inhibition of ErbB family receptors by Cl-1033 enhances the cytotoxicity of gemcitabine via modulation of AM and MAP kinases
    • Abs 1533
    • Inhibition of ErbB family receptors by Cl-1033 enhances the cytotoxicity of gemcitabine via modulation of AM and MAP kinases. Nelson JM, Fry DW PROC ANNU MEET AM ASSOC CANCER RES 2000 41 Abs 1533
    • (2000) Proc Annu Meet Am Assoc Cancer Res , vol.41
    • Nelson, J.M.1    Fry, D.W.2
  • 11
    • 33748179079 scopus 로고    scopus 로고
    • American Association for Cancer Research 91st Annual Meeting (Part XX), small molecule inhibitors of cell signaling, San Francisco, CA, USA
    • April 01-05
    • American Association for Cancer Research 91st Annual Meeting (Part XX), Small Molecule Inhibitors of Cell Signaling, San Francisco, CA, USA. Denny WA IDDB MEETING REPORT 2000 April 01-05
    • (2000) IDDB Meeting Report
    • Denny, W.A.1
  • 12
    • 0034611617 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(phenylamino)pyrido[3, 2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
    • Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(phenylamino)pyrido[3, 2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. Smail JB, Rewcastle GW, Loo JA, Greis KD, Chan OH, Reyner EL, Lipka E, Hollis Showalter HD, Vincent PW, Elliot WL, Denny WA J MED CHEM 2000 43 7 1380-1397
    • (2000) J Med Chem , vol.43 , Issue.7 , pp. 1380-1397
    • Smail, J.B.1    Rewcastle, G.W.2    Loo, J.A.3    Greis, K.D.4    Chan, O.H.5    Reyner, E.L.6    Lipka, E.7    Hollis Showalter, H.D.8    Vincent, P.W.9    Elliot, W.L.10    Denny, W.A.11
  • 13
    • 33748152520 scopus 로고    scopus 로고
    • 27th National Medicinal Chemistry Symposium, Kansas City, MO, USA
    • June 13-17
    • 27th National Medicinal Chemistry Symposium, Kansas City, MO, USA. Enuezie C IDDB MEETING REPORT 2000 June 13-17
    • (2000) IDDB Meeting Report
    • Enuezie, C.1
  • 14
    • 0005377698 scopus 로고    scopus 로고
    • Cl-1033: An irreversible inhibitor of the ErbB family of oncogenes
    • Cl-1033: An irreversible inhibitor of the ErbB family of oncogenes. Bridges AJ NAT MED CHEM SYMP 2000 S-04
    • (2000) Nat Med Chem Symp
    • Bridges, A.J.1
  • 15
    • 0035116613 scopus 로고    scopus 로고
    • Receptor tyrosine kinase inhibitors
    • Receptor tyrosine kinase inhibitors. Haluska P, Adjei AA CURR OPIN INVEST DRUGS 2001 2 2 280-286
    • (2001) Curr Opin Invest Drugs , vol.2 , Issue.2 , pp. 280-286
    • Haluska, P.1    Adjei, A.A.2
  • 16
    • 0008639966 scopus 로고    scopus 로고
    • Wall street analysts meeting
    • Pfizer Inc December 11
    • Wall Street analysts meeting. Pfizer Inc COMPANY COMMUNICATION 2000 December 11
    • (2000) Company Communication
  • 19
    • 0035253847 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor
    • Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor. Smaill JB, Showalter HD, Zhou H, Bridges AJ, McNamara DJ, Fry DW, Nelson JM, Sherwood V, Vincent PW, Roberts BJ, Elliott WL et al J MED CHEM 2001 44 3 429-440
    • (2001) J Med Chem , vol.44 , Issue.3 , pp. 429-440
    • Smaill, J.B.1    Showalter, H.D.2    Zhou, H.3    Bridges, A.J.4    McNamara, D.J.5    Fry, D.W.6    Nelson, J.M.7    Sherwood, V.8    Vincent, P.W.9    Roberts, B.J.10    Elliott, W.L.11
  • 20
    • 33748125992 scopus 로고    scopus 로고
    • American Society of Clinical Oncology - 37th Annual Meeting (Part IX), San Francisco, CA, USA
    • May 12-15
    • American Society of Clinical Oncology - 37th Annual Meeting (Part IX), San Francisco, CA, USA. Boven E IDDB MEETING REPORT 2001 May 12-15
    • (2001) IDDB Meeting Report
    • Boven, E.1
  • 21
    • 0003861630 scopus 로고    scopus 로고
    • American Society of Clinical Oncology - 37th Annual Meeting (Part XI), San Francisco, CA, USA
    • May 12-15
    • American Society of Clinical Oncology - 37th Annual Meeting (Part XI), San Francisco, CA, USA. Morse M IDDB MEETING REPORT 2001 May 12-15
    • (2001) IDDB Meeting Report
    • Morse, M.1
  • 22
    • 33748207522 scopus 로고    scopus 로고
    • Lung Cancer - Seventh Central European Conference, New Therapeutic Strategies, Prague, Czech Republic
    • June 03-06
    • Lung Cancer - Seventh Central European Conference, New Therapeutic Strategies, Prague, Czech Republic. Awada A IDDB MEETING REPORT 2001 June 03-06
    • (2001) IDDB Meeting Report
    • Awada, A.1
  • 23
    • 0003305567 scopus 로고    scopus 로고
    • Healthcare: Pharmaceuticals: Pharmaceutical Industry review
    • September 27
    • Healthcare: Pharmaceuticals: Pharmaceutical Industry Review. Rubin J, Yu N, Sone T MORGAN STANLEY DEAN WITTER 2001 September 27
    • (2001) Morgan Stanley Dean Witter
    • Rubin, J.1    Yu, N.2    Sone, T.3
  • 28
    • 0042504781 scopus 로고    scopus 로고
    • American Society of Clinical Oncology - 38th Annual Meeting (Part VI) - OVERNIGHT REPORT, Orlando, FL, USA
    • May 18-21
    • American Society of Clinical Oncology - 38th Annual Meeting (Part VI) - OVERNIGHT REPORT, Orlando, FL, USA. Ertich R IDDB MEETING REPORT 2002 May 18-21
    • (2002) IDDB Meeting Report
    • Ertich, R.1
  • 31
    • 0034853561 scopus 로고    scopus 로고
    • Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor Cl-1033
    • Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor Cl-1033. Gieseg MA, de Bock C, Ferguson LR, Denny WA ANTICANCER DRUGS 2001 12 8 683-690
    • (2001) Anticancer Drugs , vol.12 , Issue.8 , pp. 683-690
    • Gieseg, M.A.1    De Bock, C.2    Ferguson, L.R.3    Denny, W.A.4
  • 32
    • 0035168761 scopus 로고    scopus 로고
    • CM 033, a pan-erbB tyrosine kinase inhibitor
    • CM 033, a pan-erbB tyrosine kinase inhibitor. Slichenmyer WJ, Elliott WL, Fry DW SEMIN ONCOL 2001 28 5 Suppl 16 80-85
    • (2001) Semin Oncol , vol.28 , Issue.5 SUPPL. 16 , pp. 80-85
    • Slichenmyer, W.J.1    Elliott, W.L.2    Fry, D.W.3
  • 33
    • 0035256698 scopus 로고    scopus 로고
    • Untangling the ErbB signaling network
    • Untangling the ErbB signaling network. Yarden Y, Sliwkowski M NAT REV MOL CELL BIOL 2001 2 2 127-137
    • (2001) Nat Rev Mol Cell Biol , vol.2 , Issue.2 , pp. 127-137
    • Yarden, Y.1    Sliwkowski, M.2
  • 34
    • 33748170845 scopus 로고    scopus 로고
    • Signal transduction modulators in cancer therapy - First International Symposium (Part II), Amsterdam, the Netherlands
    • September 23-25
    • Signal Transduction Modulators in Cancer Therapy - First International Symposium (Part II), Amsterdam, the Netherlands. Sausville E IDDB MEETING REPORT 2002 September 23-25
    • (2002) IDDB Meeting Report
    • Sausville, E.1
  • 35
    • 33748128167 scopus 로고    scopus 로고
    • European Society for Medical Oncology - 27th Congress (Part II), Nice, France
    • IDdb Author October 18-22
    • European Society for Medical Oncology - 27th Congress (Part II), Nice, France. IDdb Author IDDB MEETING REPORT 2002 October 18-22
    • (2002) IDDB Meeting Report
  • 36
    • 33748131042 scopus 로고    scopus 로고
    • Anti-receptor signaling strategies in human neoplasia - First International Symposium, Chicago, IL, USA
    • September 19-21
    • Anti-Receptor Signaling Strategies in Human Neoplasia - First International Symposium, Chicago, IL, USA. Neel BG IDDB MEETING REPORT 2002 September 19-21
    • (2002) IDDB Meeting Report
    • Neel, B.G.1
  • 37
    • 33748139597 scopus 로고    scopus 로고
    • Pfizer 2002 annual report: Toward a healthier world
    • Pfizer Inc February 27
    • Pfizer 2002 Annual Report: Toward a Healthier World. Pfizer Inc ANNUAL REPORT 2003 February 27
    • (2003) Annual Report
  • 40
    • 0036316380 scopus 로고    scopus 로고
    • Potential benefits of the irreversible pan-ErbB inhibitor, Cl-1033, in the treatment of breast cancer
    • Potential benefits of the irreversible pan-ErbB inhibitor, Cl-1033, in the treatment of breast cancer. Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW SEMIN ONCOL 2002 29 3 Suppl 11 11-21 This study reported preclinical and clinical data that support the use of canertinib in breast cancer patients.
    • (2002) Semin Oncol , vol.29 , Issue.3 SUPPL. 11 , pp. 11-21
    • Allen, L.F.1    Lenehan, P.F.2    Eiseman, I.A.3    Elliott, W.L.4    Fry, D.W.5
  • 43
    • 84898695639 scopus 로고    scopus 로고
    • Inhibition of ErbB family receptors by Cl-1033 enhances the cytotoxicity of gemcitabine via modulation of AKT and MAP kinases
    • Abs 241
    • Inhibition of ErbB family receptors by Cl-1033 enhances the cytotoxicity of gemcitabine via modulation of AKT and MAP kinases. Nelson JM, Fry DW PROC ANNU MEET AM ASSOC CANCER RES 2000 41 Abs 241
    • (2000) Proc Annu Meet Am Assoc Cancer Res , vol.41
    • Nelson, J.M.1    Fry, D.W.2
  • 44
    • 0000300539 scopus 로고    scopus 로고
    • Effect of epidermal growth factor receptor tyrosine kinase inhibitor PD183805 on vascular endothelial growth factor secretion from several tumor models
    • Abs 141
    • Effect of epidermal growth factor receptor tyrosine kinase inhibitor PD183805 on vascular endothelial growth factor secretion from several tumor models. Driscoll D, Steinkampf R, Patmore S, Elliott W, Klohs W PROC ANNU MEET AM ASSOC CANCER RES 1999 40 Abs 141
    • (1999) Proc Annu Meet Am Assoc Cancer Res , vol.40
    • Driscoll, D.1    Steinkampf, R.2    Patmore, S.3    Elliott, W.4    Klohs, W.5
  • 46
    • 0034565927 scopus 로고    scopus 로고
    • Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor
    • Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Rao GS, Murray S, Ethier SP INT J RADIAT ONCOL BIOL PHYS 2000 48 5 1519-1528
    • (2000) Int J Radiat Oncol Biol Phys , vol.48 , Issue.5 , pp. 1519-1528
    • Rao, G.S.1    Murray, S.2    Ethier, S.P.3
  • 47
    • 33748181280 scopus 로고    scopus 로고
    • Cl-1033 a pan Erb-B family tyrosine kinase inhibitor induces apoptosis in glioblastoma cells in a non-growth arrest pattern
    • Abs 778
    • Cl-1033 a pan Erb-B family tyrosine kinase inhibitor induces apoptosis in glioblastoma cells in a non-growth arrest pattern. Allen AM, Ethier SP PROC ANNU MEET AM ASSOC CANCER RES 2003 42 Abs 778
    • (2003) Proc Annu Meet Am Assoc Cancer Res , vol.42
    • Allen, A.M.1    Ethier, S.P.2
  • 48
    • 0034600849 scopus 로고    scopus 로고
    • The ErbB signaling network: Receptor heterodimerization in development and cancer
    • The ErbB signaling network: Receptor heterodimerization in development and cancer. Olayioye M, Neve R, Lane H, Hynes NE EMBO J 2000 19 13 3159-3167
    • (2000) Embo J , vol.19 , Issue.13 , pp. 3159-3167
    • Olayioye, M.1    Neve, R.2    Lane, H.3    Hynes, N.E.4
  • 49
    • 2142654748 scopus 로고    scopus 로고
    • Administration of Cl-1033, an irreversible pan-ErbB tyrsosine kinase (TK) inhibitor is feasible on a 7-day-on/7-day-off schedule: A phase I, pharmacokinetic (PK), and food effect study
    • Abs 807
    • Administration of Cl-1033, an irreversible pan-ErbB tyrsosine kinase (TK) inhibitor is feasible on a 7-day-on/7-day-off schedule: A phase I, pharmacokinetic (PK), and food effect study. Rowinsky EK, Garrison M, Lorusso P, Patnaik A, Hammond L, De Bono J, McCreery H, Eiseman I, Lenehan P, Tolcher A PROC AM SOC CLIN ONCOL 2003 22 Abs 807
    • (2003) Proc Am Soc Clin Oncol , vol.22
    • Rowinsky, E.K.1    Garrison, M.2    Lorusso, P.3    Patnaik, A.4    Hammond, L.5    De Bono, J.6    McCreery, H.7    Eiseman, I.8    Lenehan, P.9    Tolcher, A.10
  • 51
    • 33748161941 scopus 로고    scopus 로고
    • American Urological Association - 98th Annual Meeting, Chicago, IL, USA
    • April 26-May 01
    • American Urological Association - 98th Annual Meeting, Chicago, IL, USA. Jamison J IDDB MEETING REPORT 2001 April 26-May 01
    • (2001) IDDB Meeting Report
    • Jamison, J.1
  • 53
    • 33748169436 scopus 로고    scopus 로고
    • Analyst meeting - Research and early development
    • Pfizer Inc June 17
    • Analyst meeting - research and early development Pfizer Inc COMPANY PRESENTATION 2003 June 17
    • (2003) Company Presentation
  • 54
    • 0028237507 scopus 로고
    • Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification
    • Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Ekstrand AJ, Longon N, Hamid ML, Olson JJ, Liu L, Collins VP ONCOGENE 1994 9 8 2313-2320
    • (1994) Oncogene , vol.9 , Issue.8 , pp. 2313-2320
    • Ekstrand, A.J.1    Longon, N.2    Hamid, M.L.3    Olson, J.J.4    Liu, L.5    Collins, V.P.6
  • 55
    • 0028859415 scopus 로고
    • Effect of endogenous and exogenous EGF on the growth of EGF receptor-hyperproducing human squamous cell carcinoma implanted in nude mice
    • Effect of endogenous and exogenous EGF on the growth of EGF receptor-hyperproducing human squamous cell carcinoma implanted in nude mice. Kitagawa Y, Ueda M, Ando N, Ozawa S, Kitajima M BR J CANCER 1995 72 4 865-868
    • (1995) Br J Cancer , vol.72 , Issue.4 , pp. 865-868
    • Kitagawa, Y.1    Ueda, M.2    Ando, N.3    Ozawa, S.4    Kitajima, M.5
  • 56
    • 0034234854 scopus 로고    scopus 로고
    • Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ublquitination of HER-2
    • Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ublquitination of HER-2. Klapper L, Waterman H, Sela M, Yarden Y CANCER RES 2000 60 13 3384-3388
    • (2000) Cancer Res , vol.60 , Issue.13 , pp. 3384-3388
    • Klapper, L.1    Waterman, H.2    Sela, M.3    Yarden, Y.4
  • 57
    • 0032445260 scopus 로고    scopus 로고
    • HER-2/neu as a predictive marker of response to breast cancer therapy
    • HER-2/neu as a predictive marker of response to breast cancer therapy. Pegram MD, Pauletti G, Slamon DJ BREAST CANCER RES TREAT 1998 52 1-3 65-77
    • (1998) Breast Cancer Res Treat , vol.52 , Issue.1-3 , pp. 65-77
    • Pegram, M.D.1    Pauletti, G.2    Slamon, D.J.3
  • 58
    • 0025831844 scopus 로고
    • Expression of mutant p53, c-ErbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder
    • Expression of mutant p53, c-ErbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Wright C, Mellon K, Johnston P, Lane DP, Harris AL, Horne CH, Neal DE BR J CANCER 1991 63 6 967-970
    • (1991) Br J Cancer , vol.63 , Issue.6 , pp. 967-970
    • Wright, C.1    Mellon, K.2    Johnston, P.3    Lane, D.P.4    Harris, A.L.5    Horne, C.H.6    Neal, D.E.7
  • 59
    • 33748141337 scopus 로고    scopus 로고
    • Annual research report for 1998
    • University of Auckland December 31
    • Annual research report for 1998. University of Auckland ANNUAL REPORT 1998 December 31
    • (1998) Annual Report


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.